Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 52

References for PMC Articles for PubMed (Select 21245090)

1.

Altered tissue 3'-deoxy-3'-[18F]fluorothymidine pharmacokinetics in human breast cancer following capecitabine treatment detected by positron emission tomography.

Kenny LM, Contractor KB, Stebbing J, Al-Nahhas A, Palmieri C, Shousha S, Coombes RC, Aboagye EO.

Clin Cancer Res. 2009 Nov 1;15(21):6649-57. doi: 10.1158/1078-0432.CCR-09-1213. Epub 2009 Oct 27.

2.

A sphingosine kinase inhibitor induces cell death in temozolomide resistant glioblastoma cells.

Bektas M, Johnson SP, Poe WE, Bigner DD, Friedman HS.

Cancer Chemother Pharmacol. 2009 Oct;64(5):1053-8. doi: 10.1007/s00280-009-1063-0. Epub 2009 Jul 12.

3.

Kinase Inhibitor 4 Minisymposium summary.

Dancey JE.

Expert Rev Anticancer Ther. 2009 Jul;9(7):891-4. doi: 10.1586/era.09.66.

PMID:
19589028
4.

AZD1152 rapidly and negatively affects the growth and survival of human acute myeloid leukemia cells in vitro and in vivo.

Oke A, Pearce D, Wilkinson RW, Crafter C, Odedra R, Cavenagh J, Fitzgibbon J, Lister AT, Joel S, Bonnet D.

Cancer Res. 2009 May 15;69(10):4150-8. doi: 10.1158/0008-5472.CAN-08-3203. Epub 2009 Apr 14.

5.

NCI-sponsored trial for the evaluation of safety and preliminary efficacy of 3'-deoxy-3'-[18F]fluorothymidine (FLT) as a marker of proliferation in patients with recurrent gliomas: preliminary efficacy studies.

Spence AM, Muzi M, Link JM, O'Sullivan F, Eary JF, Hoffman JM, Shankar LK, Krohn KA.

Mol Imaging Biol. 2009 Sep-Oct;11(5):343-55. doi: 10.1007/s11307-009-0215-2. Epub 2009 Mar 27.

PMID:
19326172
6.

The topoisomerase I poison CPT-11 enhances the effect of the aurora B kinase inhibitor AZD1152 both in vitro and in vivo.

Nair JS, de Stanchina E, Schwartz GK.

Clin Cancer Res. 2009 Mar 15;15(6):2022-30. doi: 10.1158/1078-0432.CCR-08-1826. Epub 2009 Mar 10.

7.

An improved method for staining cell colonies in clonogenic assays.

Guda K, Natale L, Markowitz SD.

Cytotechnology. 2007 Jun;54(2):85-8. doi: 10.1007/s10616-007-9083-2. Epub 2007 Jun 12.

8.

Imaging of viral thymidine kinase gene expression by replicating oncolytic adenovirus and prediction of therapeutic efficacy.

Kim EJ, Yoo JY, Choi YH, Ahn KJ, Lee JD, Yun CO, Yun M.

Yonsei Med J. 2008 Oct 31;49(5):811-8. doi: 10.3349/ymj.2008.49.5.811.

9.

First demonstration of leukemia imaging with the proliferation marker 18F-fluorodeoxythymidine.

Buck AK, Bommer M, Juweid ME, Glatting G, Stilgenbauer S, Mottaghy FM, Schulz M, Kull T, Bunjes D, Möller P, Döhner H, Reske SN.

J Nucl Med. 2008 Nov;49(11):1756-62. doi: 10.2967/jnumed.108.055335. Epub 2008 Oct 16.

10.

NCI-sponsored trial for the evaluation of safety and preliminary efficacy of FLT as a marker of proliferation in patients with recurrent gliomas: safety studies.

Spence AM, Muzi M, Link JM, Hoffman JM, Eary JF, Krohn KA.

Mol Imaging Biol. 2008 Sep;10(5):271-80. doi: 10.1007/s11307-008-0151-6. Epub 2008 Jun 10.

11.

Imaging bone and soft tissue tumors with the proliferation marker [18F]fluorodeoxythymidine.

Buck AK, Herrmann K, Büschenfelde CM, Juweid ME, Bischoff M, Glatting G, Weirich G, Möller P, Wester HJ, Scheidhauer K, Dechow T, Peschel C, Schwaiger M, Reske SN.

Clin Cancer Res. 2008 May 15;14(10):2970-7. doi: 10.1158/1078-0432.CCR-07-4294. Epub 2008 Apr 29.

12.

Effects of the aurora kinase inhibitors AZD1152-HQPA and ZM447439 on growth arrest and polyploidy in acute myeloid leukemia cell lines and primary blasts.

Walsby E, Walsh V, Pepper C, Burnett A, Mills K.

Haematologica. 2008 May;93(5):662-9. doi: 10.3324/haematol.12148. Epub 2008 Mar 26.

13.

Aurora kinases as anticancer drug targets.

Gautschi O, Heighway J, Mack PC, Purnell PR, Lara PN Jr, Gandara DR.

Clin Cancer Res. 2008 Mar 15;14(6):1639-48. doi: 10.1158/1078-0432.CCR-07-2179. Review.

14.

The role of the AMP-activated protein kinase in the regulation of energy homeostasis.

Carling D.

Novartis Found Symp. 2007;286:72-81; discussion 81-5, 162-3, 196-203.

PMID:
18269175
15.

A multicenter clinical trial on the diagnostic value of dual-tracer PET/CT in pulmonary lesions using 3'-deoxy-3'-18F-fluorothymidine and 18F-FDG.

Tian J, Yang X, Yu L, Chen P, Xin J, Ma L, Feng H, Tan Y, Zhao Z, Wu W.

J Nucl Med. 2008 Feb;49(2):186-94. doi: 10.2967/jnumed.107.044966. Epub 2008 Jan 16.

16.

Mechanism of action of the Aurora kinase inhibitor CCT129202 and in vivo quantification of biological activity.

Chan F, Sun C, Perumal M, Nguyen QD, Bavetsias V, McDonald E, Martins V, Wilsher NE, Raynaud FI, Valenti M, Eccles S, Te Poele R, Workman P, Aboagye EO, Linardopoulos S.

Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3147-57.

17.

The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma.

Evans RP, Naber C, Steffler T, Checkland T, Maxwell CA, Keats JJ, Belch AR, Pilarski LM, Lai R, Reiman T.

Br J Haematol. 2008 Feb;140(3):295-302. Epub 2007 Dec 10.

PMID:
18076711
18.

AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis.

Wilkinson RW, Odedra R, Heaton SP, Wedge SR, Keen NJ, Crafter C, Foster JR, Brady MC, Bigley A, Brown E, Byth KF, Barrass NC, Mundt KE, Foote KM, Heron NM, Jung FH, Mortlock AA, Boyle FT, Green S.

Clin Cancer Res. 2007 Jun 15;13(12):3682-8.

19.

AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo.

Yang J, Ikezoe T, Nishioka C, Tasaka T, Taniguchi A, Kuwayama Y, Komatsu N, Bandobashi K, Togitani K, Koeffler HP, Taguchi H, Yokoyama A.

Blood. 2007 Sep 15;110(6):2034-40. Epub 2007 May 10.

20.

Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinase.

Mortlock AA, Foote KM, Heron NM, Jung FH, Pasquet G, Lohmann JJ, Warin N, Renaud F, De Savi C, Roberts NJ, Johnson T, Dousson CB, Hill GB, Perkins D, Hatter G, Wilkinson RW, Wedge SR, Heaton SP, Odedra R, Keen NJ, Crafter C, Brown E, Thompson K, Brightwell S, Khatri L, Brady MC, Kearney S, McKillop D, Rhead S, Parry T, Green S.

J Med Chem. 2007 May 3;50(9):2213-24. Epub 2007 Mar 21.

PMID:
17373783
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk